. Author manuscript; available in PMC: 2009 Nov 25.

Published in final edited form as: J Agric Food Chem. 2008 Jun 21;56(14):5550–5557. doi: 10.1021/jf800105c

Table 2.

Pharmacokinetic Parameters of Total Hesperetin After Single IV Administration of Hesperidin or Hesperetin or Hesperidin Treated with Different BlgA Protein Treatment

Parameters	Pure Hesperidin	Pure Hesperetin	Hesperidin Extract untreated	Hesperidin Extract+BlgA from E. Coli	Hesperidin Extract+BlgA from yeast
AUC_obs AVG (nmol · hr/ml) SD	30.09	61.47 ^a	18.01	59.40 ^b	57.90 ^b
AUC_obs AVG (nmol · hr/ml) SD	12.88	22.20	10.86	14.68	11.73
Half-life AVG (hr) SD	6.28	6.52	6.25	6.05	6.15
Half-life AVG (hr) SD	0.28	0.61	0.81	1.01	0.32
V_z AVG (ml) SD	10.73	5.40 ^a	19.27	4.70 ^b	4.88 ^b
V_z AVG (ml) SD	4.34	2.42	7.44	0.47	0.82
CL AVG (ml/hr) SD	1.17	0.56 ^a	2.10	0.54 ^b	0.55 ^b
CL AVG (ml/hr) SD	0.43	0.22	0.81	0.11	0.09

There are statistically significant differences between AUC_0bs for pure hesperidin and pure hesperetin (p<0.05).

There are statistically significant differences between AUC_0bs, V_z, CL for hesperidin with different BlgA protein treatment and untreated hesperidin extract (P<0.05).